Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016

BACKGROUND: To evaluate factors affecting the utilization of immunotherapy and to stratify results based on the approval of ipilimumab in 2011 and programmed death-1 inhibitors in 2014, an analysis of available data from the National Cancer Database (NCDB) was performed. METHODS: The NCDB was analyz...

Descripción completa

Detalles Bibliográficos
Autores principales: Sussman, Tamara A, Knackstedt, Rebecca, Wei, Wei, Funchain, Pauline, Gastman, Brian R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403163/
https://www.ncbi.nlm.nih.gov/pubmed/35998982
http://dx.doi.org/10.1136/jitc-2022-004994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403163/
https://www.ncbi.nlm.nih.gov/pubmed/35998982
http://dx.doi.org/10.1136/jitc-2022-004994

Ejemplares similares